Cumberland’s sclerosis study supports safety but cannot establish efficacy
Cumberland Pharmaceuticals ($CPIX) reported results from its 12-month ASSIST-SSc pilot study of oral ifetroban in systemic sclerosis. Thirty-one participants received the drug and ten received placebo. The company described tolerability as broadly consistent with earlier experience, with more gastrointestinal events and a modest increase in bleeding-related events on treatment; these were predominantly mild. No serious event during treatment was judged related to the study drug. The Phase 2a tri
0